Article
Oncology
Kyung Min Lee, Alex K. Bryant, Julie A. Lynch, Brian Robison, Patrick R. Alba, Fatai Y. Agiri, Kathryn M. Pridgen, Scott L. DuVall, Kosj Yamoah, Isla P. Garraway, Brent S. Rose
Summary: The study found that, at any given PSA level, Black men are more likely to develop prostate cancer than White men.
Article
Oncology
Jaegeun Lee, Seung Woo Yang, Long Jin, Chung Lyul Lee, Ji Yong Lee, Ju Hyun Shin, Jae Sung Lim, Ki Hak Song
Summary: The study suggests that PSAD and ETzD may be more sensitive and accurate than traditional PSA for patients with gray zone PSA levels undergoing prostate biopsy. Increasing the cut-off values of PSAD and ETzD helps reduce unnecessary prostate biopsies.
Article
Biochemistry & Molecular Biology
Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte
Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.
Article
Oncology
Naseruddin Hoti, Tung-Shing Lih, Mingming Dong, Zhen Zhang, Leslie Mangold, Alan W. Partin, Lori J. Sokoll, Qing Kay Li, Hui Zhang
Summary: Prostate cancer is a leading cause of death in men in the United States. The commonly used method of diagnosis involves digital rectal examination and serum PSA assay, followed by prostate gland biopsy. However, false elevations in PSA levels can lead to unnecessary biopsies. This study evaluated the use of urinary PSA as a predictive marker for aggressive prostate cancer, and found that it had higher predictive power compared to serum PSA. Combining serum and urinary PSA levels further enhanced the detection of aggressive prostate cancer.
Article
Oncology
James W. Frisbie, Alexa J. Van Besien, Adrianna Lee, Linhan Xu, Shu Wang, Ankur Choksi, M. Adil Afzal, Michael J. Naslund, Barton Lane, Jade Wong, Amelia Wnorowski, Mohummad Minhaj Siddiqui
Summary: The study shows that prostate MP-MRI and PSA can complement each other and provide useful information for risk stratification of clinically significant prostate cancer (CSPC). PSAD value of 0.1 ng/ml/cc can serve as a useful biomarker for adjunctive risk assessment to prostate MP-MRI for CSPC.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Irena Abramovic, Borna Vrhovec, Lucija Skara, Alen Vrtaric, Nora Nikolac Gabaj, Tomislav Kulis, Goran Stimac, Dejan Ljiljak, Boris Ruzic, Zeljko Kastelan, Bozo Kruslin, Floriana Bulic-Jakus, Monika Ulamec, Ana Katusic-Bojanac, Nino Sincic
Summary: Prostate cancer is the most commonly diagnosed neoplasm among men, often resembling benign prostate hyperplasia, necessitating the need for biomarkers with higher differential value. Epigenetic biomarkers in liquid biopsies, especially miRNA, show promise in addressing this challenge. MiR-182-5p and miR-375-3p in blood plasma demonstrate higher performance than PSA in discriminating between PCa and BPH. Further investigation into seminal plasma as a potential source for PCa biomarkers is warranted.
Article
Multidisciplinary Sciences
Jian-Guo Zhong, Lin Shi, Jing Liu, Fang Cao, Yan-Qing Ma, Yang Zhang
Summary: Developing an MRI-based radiomics model to predict prostate cancer in men with PSA levels of 4-10 ng/mL, comparing its performance with PI-RADS v2.1, and verifying its predictive ability for lesions with different PI-RADS v2.1 scores.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Zengni Ma, Xinchao Wang, Wanchun Zhang, Kaisheng Gao, Le Wang, Lixia Qian, Jingjun Mu, Zhongyi Zheng, Xiaoming Cao
Summary: The study constructed a predictive model for clinically significant prostate cancer (csPCa) and found that the model, which combines age, PSAD, and PI-RADS v2.1 scores, showed excellent clinical efficacy in reducing unnecessary prostate biopsies. The model accurately predicted csPCa and outperformed other predictive factors such as PI-RADS v2.1 scores and PSAD.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Davide Maffei, Francesco Giganti, Caroline M. Moore
Summary: Prostate cancer is the most common cancer in men in Europe and many countries worldwide, and the second leading cause of cancer-related death. This article discusses the advances in MRI imaging and its potential role as a screening tool for prostate cancer, considering whether MRI can be used before biopsy or as a primary screening method.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Medicine, General & Internal
Qiang Wu, Fanglong Li, Xiaotao Yin, Jiangping Gao, Xu Zhang
Summary: This study aimed to construct a nomogram for predicting prostate cancer in patients with PSA <= 20 ng/mL at initial biopsy, which was developed based on predictors assessed by multivariable logistic regression analysis and validated through receiver operating characteristic curve, calibration plots, and decision curve analysis. The nomogram showed high predictive accuracy and could avoid unnecessary biopsies for 42.5% of patients while missing only 4.4% of PCa cases.
Article
Oncology
Jonathan Li, Dattatraya Patil, Martin G. Sanda, Christopher P. Filson
Summary: This study characterized population-level cancer-specific outcomes for prostate cancer patients based on the use of prebiopsy prostate MRI. The results showed that prebiopsy MRI can marginally increase the detection of significant cancer on biopsy and increase the likelihood of receiving a prostatectomy. However, the use of prebiopsy MRI was not associated with a greater likelihood of accurate risk classification or grade concordance between biopsy and final pathology results for those treated with prostatectomy.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Medicine, General & Internal
Jonas Hugosson, Marianne Mansson, Jonas Wallstrom, Ulrika Axcrona, Sigrid V. Carlsson, Lars Egevad, Kjell Geterud, Ali Khatami, Kimia Kohestani, Carl-Gustaf Pihl, Andreas Socratous, Johan Stranne, Rebecka Arnsrud Godtman, Mikael Hellstrom
Summary: MRI-directed targeted biopsy for prostate cancer screening reduces the risk of overdiagnosis by half compared to systematic biopsy, but may delay the detection of intermediate-risk tumors in a small proportion of patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biophysics
Ana Diaz-Fernandez, Rebeca Miranda-Castro, Noemi de-los-Santos-Alvarez, Maria Jesus Lobo-Castanon, Pedro Estrela
Summary: The study presents an improved impedimetric aptamer-based sensor for dual recognition of PSA with two different aptamers, showing a dynamic range in serum between 0.26 and 62.5 ng/mL with good reproducibility. The platform could be used as a minimally invasive method for the diagnosis of prostate cancer, as it demonstrates excellent correlation between glycan score and the known diagnosis of patients with different pathologies.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Oncology
Maurizia Mello-Grand, Antonino Bruno, Lidia Sacchetto, Simone Cristoni, Ilaria Gregnanin, Alessandro Dematteis, Andrea Zitella, Paolo Gontero, Caterina Peraldo-Neia, Riccardo Ricotta, Douglas M. Noonan, Adriana Albini, Giovanna Chiorino
Summary: A novel minimally invasive liquid biopsy-based tool was developed to characterize new metabolites and identify potential non-invasive biomarkers for better prediction of prostate cancer, especially when PSA is uninformative for precision medicine in genitourinary cancers.
FRONTIERS IN ONCOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Jung Jae Park, Chan Kyo Kim
Summary: This article reviews recent literature on the diagnostic value of pre-biopsy prostate MRI as a triage tool and discusses unresolved issues regarding the paradigm shift in the diagnosis of prostate cancer.
KOREAN JOURNAL OF RADIOLOGY
(2022)
